# EDGAR Filing Document

**Accession Number:** 0001949257
**File Stem:** 0001213900-25-104913
**Filing Date:** 2025-11
**Character Count:** 14305
**Document Hash:** a1219774b42ca37dfd1f5a409de58dd9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-104913.hdr.sgml**: 20251103

**ACCESSION NUMBER**: 0001213900-25-104913

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20251103

**FILED AS OF DATE**: 20251103

**DATE AS OF CHANGE**: 20251103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Radiopharm Theranostics Ltd
- **CENTRAL INDEX KEY:** 0001949257
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41621
- **FILM NUMBER:** 251442158

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 62 LYGON STREET
- **CITY:** CARLTON VIC
- **PROVINCE COUNTRY:** C3
- **ZIP:** 3053
- **BUSINESS PHONE:** 61 3 9824 5254

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 62 LYGON STREET
- **CITY:** CARLTON VIC
- **PROVINCE COUNTRY:** C3
- **ZIP:** 3053

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER**

**THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of November 2025

Commission File Number: 001-41621

**<u>RADIOPHARM THERANOSTICS LIMITED</u>**

(Name of Registrant)

**<u>Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia</u>**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

**RADIOPHARM THERANOSTICS LIMITED**

**<u>EXPLANATORY NOTE</u>**

Radiopharm Theranostics Limited (the "Company") published two announcements (the "Public Notice") to the Australian Securities Exchange on November 3, 2025 titled:

"Change of Director's Interest Notice (RC)"

"Presenting at Deutsche Bank ADR Virtual Investor Conference"

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit** <br> **Number** | **Description** |
| 99.1 | [Change of Director's Interest Notice (RC)](ea026357201ex99-1_radiopharm.htm) |
| 99.2 | [Presenting at Deutsche Bank ADR Virtual Investor Conference](ea026357201ex99-2_radiopharm.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **RADIOPHARM THERANOSTICS LIMITED** | **RADIOPHARM THERANOSTICS LIMITED** |
| Date: November 3, 2025 | By: | /s/ Phillip Hains |
|  |  | Phillip Hains |
|  |  | Company Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

**Appendix 3Y**

**Change of Director's Interest Notice**

*Rule 3.19A.2*

**Appendix 3Y**

**Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

**Introduced 30/9/2001. Amended 01/01/11**

---

| | |
|:---|:---|
| **Name of Entity:**  | Radiopharm Theranostics Limited (ASX: RAD) |
| **ABN:** | 57 647 877 889 |

---

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

---

| | |
|:---|:---|
| **Name of Director:** | Riccardo Canevari |
| **Date of Last Notice:** | 18 December 2024 |

---

**Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Direct or Indirect Interest** | &nbsp;&nbsp;Indirect | &nbsp;&nbsp;Indirect | &nbsp;&nbsp;Indirect |
| &nbsp;&nbsp;**Nature of indirect interest**<br> **(including registered holder)**<br> Note: Provide details of the circumstances giving rise to the relevant interest. | &nbsp;&nbsp;Indirect interest held via broker nominee account | &nbsp;&nbsp;Indirect interest held via broker nominee account | &nbsp;&nbsp;Indirect interest held via broker nominee account |
| &nbsp;&nbsp;**Date of change** | &nbsp;&nbsp;30 October 2025 | &nbsp;&nbsp;30 October 2025 | &nbsp;&nbsp;30 October 2025 |
| &nbsp;&nbsp;**No. of securities held prior to change** |  | **Shares** | **Options** |
|  | &nbsp;&nbsp;Direct | 20029986 | 110949299 |
|  | &nbsp;&nbsp;Indirect | 1150000 | - |
|  | &nbsp;&nbsp;**Total** | **21179986** | **110949299** |
| &nbsp;&nbsp;**Class** | &nbsp;&nbsp;RAD ORDINARY FULLY PAID SHARES | &nbsp;&nbsp;RAD ORDINARY FULLY PAID SHARES | &nbsp;&nbsp;RAD ORDINARY FULLY PAID SHARES |
| &nbsp;&nbsp;**Number acquired** |  | **Shares** | **Options** |
|  | &nbsp;&nbsp;Direct | - | - |
|  | &nbsp;&nbsp;Indirect | 1500000 | - |
|  | &nbsp;&nbsp;**Total** | **1500000** | **-** |
| &nbsp;&nbsp;**Number disposed** |  | **Shares** | **Options** |
|  | &nbsp;&nbsp;Direct | - | - |
|  | &nbsp;&nbsp;Indirect | - | - |
|  | &nbsp;&nbsp;**Total** | **-** | **-** |
| &nbsp;&nbsp;**Value/Consideration**<br> Note:<br> If consideration is non-cash, provide details and estimated valuation | &nbsp;&nbsp;$0.025 per share | &nbsp;&nbsp;$0.025 per share | &nbsp;&nbsp;$0.025 per share |

---

+ See chapter 19 for defined terms. <br>01/01/2011 Appendix 3Y Page 1

**Appendix 3Y**

**Change of Director's Interest Notice**

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**No. of securities held after change** | | **Shares** | **Options** |
|  | &nbsp;&nbsp;Direct | 20029986 | 110949299 |
|  | &nbsp;&nbsp;Indirect | 2650000 | - |
|  | &nbsp;&nbsp;**Total** | **22679986** | **110949299** |
| &nbsp;&nbsp;**Nature of change**<br> Example:<br> on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | &nbsp;&nbsp;On-market trade | &nbsp;&nbsp;On-market trade | &nbsp;&nbsp;On-market trade |

---

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

---

| | |
|:---|:---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
|  **Name of registered holder**<br> **(if issued securities)** | N/A |
| **Date of change** | N/A |
|  **No. and class of securities to which interest related prior to change**<br> Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
|  **Value/Consideration**<br> Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

---

+ See chapter 19 for defined terms. <br>Appendix 3Y Page 2 01/01/2011

**Appendix 3Y**

**Change of Director's Interest Notice**

**Part 3 – Closed period**

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | &nbsp;&nbsp;No |
| &nbsp;&nbsp;**If so, was prior written clearance provided to allow the trade to proceed during this period?** | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;**If prior written clearance was provided, on what date was this provided?** | &nbsp;&nbsp;N/A |

---

+ See chapter 19 for defined terms. <br>01/01/2011 Appendix 3Y Page 3

## Exhibit 99.2

**Exhibit 99.2**

---

| | |
|:---|:---|
| **ASX ANNOUNCEMENT<br> **3 NOVEMBER 2025** | ![](ex99-2_001.jpg) |

---

**Radiopharm Theranostics to Present at the dbVIC — Deutsche Bank ADR Virtual Investor Conference**

*Individual and institutional investors, advisors and analysts invited to attend online at VirtualInvestorConferences.com*

**Sydney, Australia – 3 November 2025** – Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that Riccardo Canevari, Chief Executive Officer and Managing Director of Radiopharm Theranostics, will present live at the dbVIC – Deutsch Bank American Depositary Receipt (ADR) Virtual Investor Conference.

The event is being hosted by VirtualInvestorConferences.com on 4 November 2025. This virtual conference program is aimed exclusively at introducing global companies with ADR programs to investors.

**DATE**: Tuesday 4 November 2025

**TIME:** 12:30pm EST (US) / 4:30am AEDT, Wednesday 5 November 2025 (Sydney)

**LINK:** Click here to visit the website and register

This will be a live, interactive online event where investors are invited to ask management questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Participation is free of charge.

**Recent Company Highlights**

● Raised approximately A$35 million in capital through an institutional private placement to new Australian and international investors with a potential A$5 million through a Share Purchase Plan for existing shareholders in Australia and New Zealand.

● Reported preliminary data from the first three patients in a Phase 2b imaging clinical trial of RAD 101 that showed uptake in brain metastases from solid tumours, confirming proof-of-concept with Phase 2 topline results expected by H1 2026.

● Announced that the first cohort of patients in its Phase 1 clinical trial of RAD 202 (HER2) showed a higher-than-expected tumour uptake, with a second cohort of patients anticipated to be fully enrolled with data available by year-end 2025.

● Highlighted additional data from the first six patients in a Phase 1 clinical trial of RAD 204 (PDL-1), which showed promising tumour uptake.

● Noted data from the Phase 1 study of RAD 301 supported the decision to advance to a Phase 2 imaging trial in patients with loco-regional pancreatic cancer.

**Radiopharm Theranostics Limited<br> Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia<br> ABN: 57 647 877 889**

---

| | |
|:---|:---|
| **ASX ANNOUNCEMENT<br> **3 NOVEMBER 2025** | ![](ex99-2_001.jpg) |

---

**About Radiopharm Theranostics**

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.

**About Virtual Investor Conferences<sup>®</sup>**

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

**Authorised on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.**

**For more information:**

**Investors:**

Riccardo Canevari<br> CEO & Managing Director<br> P: +1 862 309 0293<br> E: rc@radiopharmtheranostics.com

Anne Marie Fields<br> Precision AQ<br> (Formerly Stern IR)<br> E: annemarie.fields@precisionaq.com

**Media:**

Matt Wright<br> NWR Communications<br> P: +61 451 896 420<br> E: matt@nwrcommunications.com.au

**Virtual Investor Conferences** 

John M. Viglotti

SVP Corporate Services, Investor Access

OTC Markets Group

(212) 220-2221

johnv@otcmarkets.com

**Radiopharm Theranostics Limited<br> Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia<br> ABN: 57 647 877 889**

---

| | |
|:---|:---|
| **ASX ANNOUNCEMENT<br> **3 NOVEMBER 2025** | ![](ex99-2_001.jpg) |

---

**Follow Radiopharm Theranostics:** 

Website – https://radiopharmtheranostics.com/<br> Twitter – https://twitter.com/TeamRadiopharm<br> Linked In – https://www.linkedin.com/company/radiopharm-theranostics/<br> InvestorHub – https://investorhub.radiopharmtheranostics.com/

**Radiopharm Theranostics Limited<br> Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia<br> ABN: 57 647 877 889**